Novasecta’s Managing Partner, John Rountree, was asked by CNBC to comment on Takeda’s takeover of Shire, in which he reflects on “M&A becoming very expensive in pharma” and how the “innovation problem drives M&A in the sector”, both issues Novasecta has previously highlighted.
To read our insight into the cost of pharma M&A click here or for R&D innovation click here.
Insights
Takeda’s takeover of Shire (CNBC)
Novasecta’s Managing Partner, John Rountree, was asked by CNBC to comment on Takeda’s takeover of Shire, in which he reflects on “M&A becoming very expensive in pharma” and how the “innovation problem drives M&A in the sector”, both issues Novasecta has previously highlighted.
To read our insight into the cost of pharma M&A click here or for R&D innovation click here.
Related
Insights
Sandoz will be a long-term stable business if it can get its cost structure right (CNBC)
DiscoverPharma/Biotech R&D Effectiveness: What it Takes – Exclusive Workshop
DiscoverHow European MidPharmas have grown profits
Discover